Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF used

Abstract

SummaryMobilised peripheral blood is now the main source of stem cells collected from normal donors. We report our experience of mobilising and collecting 400 normal healthy donors using standardised procedures and techniques. Target recipient doses were reached with one aphaeresis in 63% of donors and with two aphereses in 81% of donors. Approximately 2% of donors yielded such low progenitor values that they were termed 'poor mobilisers'. There were minor effects of donor age, weight and sex and where possible, larger male donors under the age of 55 years should be selected. Two forms of granulocyte colony-stimulating factor (G-CSF) were used at the same dose and no significant difference was seen in the yield of CD34 + cells collected/l of blood processed. However, a greater number of granulocyte-macrophage colony-forming cells were harvested using lenograstim (glycosylated G-CSF) compared with filgrastim (non-glycosylated G-CSF; P ¼ 0AE002). CD34 + cell yields were also measured halfway through the aphaeresis procedure. This was found to be highly predictive of final yield and facilitated distribution of the stem cell product to other centres. The observation that CD34 + yields did not decline in the second half compared with the first half of aphaeresis suggests that the circulating cell numbers are not static.

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

“…Pulsipher and colleagues reported that among 2,408 unrelated donors of PBSCs, two-thirds (66%) underwent two apheresis procedures, whereas the remaining donors completed their donations in a single day (19). Ings and colleagues reported that among 400 unrelated donors of PBSCs target recipient doses were reached with one aphaeresis in 63% of donors and with two apheresis in 81% of donors; 19% of the donors needed more than two apheresis (20). AMD3100 (plerixafor, Mozobil) is a reversible direct antagonist of the interaction between the chemokine SDF-1 and its receptor CXCR4 and is used for HSPC mobilization.…”

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

“…This study looked for differences in HPC mobilization in response to glycosylated Hu or nonglycosylated rHu G-CSF in patients with hematological tumors that are the most frequent candidates for auto-SCT and that require combined mobilization with chemotherapy and G-CSF. The appropriate schedule of mobilization in terms of type of chemotherapy, doses and timing of G-CSF administration has been discussed in several studies, 3,18,[21][22][23][24][25][26] whereas the role of G-CSF glycosylation is still not well defined.…”

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors

“…In accordance with the literature, mobilization and harvest of CD34 ϩ cells were significantly more effective in male than in female donors. [16][17][18] Future research could identify genetic factors that would predict which donors are likely to fail adequate mobilization. One could envision alternative mobilization regimens 19 or decide for bone marrow collection.…”